CoChat

The DOI matches its Crossref record; 93 of the 97 references it cites were found in a registry or an index.

Bladder Cancer: A Review

Lenis, Andrew T., Lec, Patrick M., Chamie, Karim, MSHS, MD, · 2020 · JAMA

Abstract

IMPORTANCE: Bladder cancer is a common malignancy in women and is the fourth most common malignancy in men. Bladder cancer ranges from unaggressive and usually noninvasive tumors that recur and commit patients to long-term invasive surveillance, to aggressive and invasive tumors with high disease-specific mortality. OBSERVATIONS: Advanced age, male sex, and cigarette smoking contribute to the development of bladder cancer. Bladder tumors can present with gross or microscopic hematuria, which is evaluated with cystoscopy and upper tract imaging depending on the degree of hematuria and risk of malignancy. Non-muscle-invasive tumors are treated with endoscopic resection and adjuvant intravesical therapy, depending on the risk classification. Enhanced cystoscopy includes technology used to improve the detection of tumors and can reduce the risk of recurrence. Patients with high-risk non-muscle invasive tumors that do not respond to adjuvant therapy with the standard-of-care immunotherapy, bacille Calmette-Guérin (BCG), constitute a challenging patient population to manage and many alternative therapies are being studied. For patients with muscle-invasive disease, more aggressive therapy with radical cystectomy and urinary diversion or trimodal therapy with maximal endoscopic resection, radiosensitizing chemotherapy, and radiation is warranted to curb the risk of metastasis and disease-specific mortality. Treatment of patients with advanced disease is undergoing rapid changes as immunotherapy with checkpoint inhibitors, targeted therapies, and antibody-drug conjugates have become options for certain patients with various stages of disease. CONCLUSIONS AND RELEVANCE: Improved understanding of the molecular biology and genetics of bladder cancer has evolved the way localized and advanced disease is diagnosed and treated. While intravesical BCG has remained the mainstay of therapy for intermediate and high-risk non-muscle-invasive bladder cancer, the therapeutic options for muscle-invasive and advanced disease has expanded to include immunotherapy with checkpoint inhibition, targeted therapies, and antibody-drug conjugates.

Overview

Integrity signals

Registry

Crossref · 10.1001/jama.2020.17598

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Research works printed but not linked: 3

  1. Chang, 2017, Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline., J Urol., 198, 552, 10.1016/j.juro.2017.04.086 · DOI · Paper page
  2. von der Maase, 2000, Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study., J Clin Oncol, 18, 3068, 10.1200/jco.2000.18.17.3068 · DOI · Paper page
  3. Oxford Centre for Evidence-based Medicine: levels of evidence. Updated March 2009. Accessed June 28, 2020. https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/

Cited by

See all 2,051

Metadata

Authors
Lenis, A. T., Lec, P. M., Chamie, K., & MSHS, M.
Affiliations
  • University of California, Los Angeles (US)
  • Institute of Urologic Oncology (IUO), Department of Urology, David Geffen School of Medicine, University of California, Los Angeles
Venue
JAMA
Published
2020-11-17
Volume
324
Issue
19
Pages
1980
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W3102493364
Cited by
2,051
References
97
Citations by year
2026: 270 · 2025: 311 · 2024: 491 · 2023: 436 · 2022: 408 · 2021: 134
FWCI
49.24
Type
journal article
Language
en
Open access
closed
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
  • Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
  • Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
Keywords
bladder cancer, non-muscle-invasive bladder cancer, muscle-invasive bladder cancer, hematuria, cystoscopy, intravesical therapy, BCG vaccine, radical cystectomy, trimodality therapy, immunotherapy, immune checkpoint inhibitors, targeted therapy, antibody-drug conjugates, risk classification, recurrence, molecular genetics
MeSH terms
Administration, Intravesical, Antineoplastic Agents, BCG Vaccine, Urinary Bladder, Urinary Bladder Neoplasms, Combined Modality Therapy, Cystoscopy, Female, Humans, Immunotherapy, Male, Mutation, Neoplasm Invasiveness, Risk Factors, Cystectomy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.